MDMA THERAPY

Anyone who delves into psychedelics and entactogens soon encounters the question: how does it differ mdma actually of 2C-B and psilocybin, if you look at intensity, duration, and the balance between pleasant and difficult effects? A recent double-blind study in which these substances were directly compared with each other in 24 healthy participants provides an interesting, relatively “pure” starting point for this. It is important to remember, however, that research outcomes say something about averages in a controlled setting, and not automatically about how someone will experience it in practice or in a therapeutic context.

In this article, we summarize the key patterns from that study and put them into perspective. We distinguish between: (1) what was measured in the study, (2) what people often describe as their experience, and (3) what this may mean for safety and harm reduction. MDMA sessions can currently only be discussed within scientific research or in practice through harm reduction. This article is for informational purposes only and is not individual medical advice.

What exactly was investigated?

In the study, 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin were compared under double-blind conditions. Participants were healthy volunteers. Measurements were taken at multiple time points regarding the intensity of the sensation of “something,” how positively or negatively those effects were perceived, and which specific dimensions came to the fore, such as anxiety, nausea, social connectedness, and changes in perception.

An important advantage of this type of design is that resources are placed directly side-by-side within the same study, with comparable measurement points. At the same time, it is a limitation that the participants were healthy and that the setting was a research context. This differs from a therapeutic setting, where intention, guidance, and personal history can play a greater role.

Anyone who wants to read the source themselves can do so via How 2C‑B, MDMA, and psilocybin feel different according to research. Below, we explain the key findings in plain language.

Intensity: “I feel that something is happening”

One of the most basic measurements in the study was “any drug effect”: how clearly someone notices that the substance is working, regardless of whether that is pleasant or unpleasant. In terms of overall intensity, psilocybin scored the highest. On average, participants felt most distinctly under the influence with psilocybin, followed by 2C-B 30 mg, with MDMA just below that.

This is a useful nuance. In conversations, MDMA is sometimes experienced as “very intense,” but intensity can have different meanings. For example, MDMA can be emotionally intense without strong visual or perceptual changes. Psilocybin, on the other hand, can evoke a broader, all-encompassing change in perception and meaning-making, which often comes across as “stronger” in this type of measurement.

Duration and course: build-up, peak, and decline

The graphs in the study show not only the magnitude of effects but also the progression over time. The general picture is that psilocybin lasts longer and provides a broader range of “time under the influence.” MDMA can score relatively strongly on the feeling of being “high” in the early part of the experience, but psilocybin generally continues to work longer and can be experienced as equally strong or stronger later in the session.

For harm reduction, that duration is relevant: being under the influence longer often means remaining vulnerable to overstimulation, fatigue, and difficult moments for a longer period. A longer experience also places greater demands on the set and setting, planning, and afterward support. Conversely, a shorter experience is not necessarily “easier,” but it does represent a different logistical and mental burden.

Pleasant versus unpleasant effects: not only “how strong”, but also “how bearable”

In the study, a distinction was made between “good drug effects” and “bad drug effects”. Psilocybin scored highest on pleasant effects, but also highest on unpleasant effects. In other words: the substance that, on average, evokes the most positive dimensions is also most often associated with difficult moments.

MDMA and 2C-B (particularly the lower dosages) scored lower on unpleasant effects than psilocybin. This does not mean that MDMA or 2C-B cannot cause difficult experiences, but in this specific setup and dosages, anxious or clearly negative effects were less prominent.

An important caveat is that “bad drug effect” in questionnaires is not the same as “therapeutically difficult but valuable.” In therapy-like processes, a difficult moment can sometimes be viewed as meaningful in retrospect. Research questionnaires do not always capture this well. They primarily measure the immediate experience.

Anxiety and nausea: clear differences between remedies

Two outcomes that are very concrete for many people are anxiety and nausea. In the study, psilocybin was most strongly associated with both: more anxiety and more nausea than the other conditions. 2C-B 30 mg often came in second place. MDMA remained relatively low on these scales.

For safety and harm reduction, these are not details. Anxiety can strongly color the course of a session, and nausea can be both physically taxing and mentally disruptive. At the same time, it is unpredictable who will or will not be affected by this. Factors such as sleep, diet, stress level, setting, previous experiences, and individual sensitivity may play a role, but it remains uncertain.

Perception and “ego” effects: where psilocybin dominates

In the panels on visual and auditory changes, altered perception, and ego dissolution, psilocybin was the most pronounced. This is in line with how psilocybin is typically classified: a classic psychedelic substance that can strongly interfere with perception and self-experience.

2C-B 30 mg also showed clear psychedelic characteristics, but on average less broad and less intense than psilocybin. MDMA was below that and was more subtle in this domain. This fits the profile of MDMA as an entactogen: often placing more emphasis on mood, connectedness, and emotional accessibility than on heavy visual changes.

This distinction is relevant when considering what someone seeks or can handle. For example, someone might be open to emotional depth but not to strong distortion of the senses and sense of self. Conversely, someone might believe they benefit from meaningful, symbolic, or “mystical” layers, but must then also take into account a greater risk of being overwhelmed.

Social effects: openness and proximity

A striking part of the study concerned social feelings: openness, connectedness, the desire to be with others, and conversely, the desire to be alone. MDMA and 30 mg of 2C-B primarily increased openness and closeness. Psilocybin also showed positive social effects, but at this dose, it was simultaneously associated more frequently with introspection and a greater tendency to withdraw.

This is an important nuanced difference. In many contexts, MDMA is associated with empathy, connection, and making emotions easier to discuss. Psilocybin can also evoke a sense of connection, but it can also be an “inward-focused” journey in which contact with the outside world is less central. That is neither better nor worse, but it does involve a different dynamic in the guidance process.

Post-process questionnaires: positive, difficult, and mystical dimensions

In addition to moment-to-moment measurements, standardized questionnaires were used to retrospectively score positive effects, distress (difficult effects), perceptual effects, and mystical or spiritual dimensions.

The pattern remained consistent. Psilocybin scored highest on many positive subscales, including sense of unity, spiritual experience, and insight, and also highest on mystical experience scales. At the same time, psilocybin also scored higher on distress and anxiety. 2C-B 30 mg often occupied a middle position, clearly above MDMA on psychedelic and mystical dimensions, but on average less intense and less burdensome than psilocybin. MDMA scored lower on the classic “mystical” scales, and generally remained lower on distress than psilocybin.

It is important to emphasize: such scales describe averages and categories. They do not imply that an MDMA experience cannot be deep or meaningful, or that a psilocybin experience is by definition “heavier.” They primarily provide direction regarding what, in a controlled setting, comes to the forefront more frequently.

What does this mean for therapy and counseling (without claims)?

The study itself did not focus on therapy, but the outcomes are often used to reflect on suitability in supervised contexts. If we translate this very cautiously to practical questions, the results primarily help with one thing: making trade-offs explicit.

At this dosage, psilocybin appears on average to offer a greater chance of intensity, profound perceptual change, and mystical experiences, while simultaneously carrying a greater risk of anxiety, nausea, and difficult moments. In this study, MDMA generally shows a profile with relatively low anxiety and strong social and emotional opening, but less pronounced perceptual and mystical effects. 2C-B 30 mg falls in between and appears to combine both entactogenic and psychedelic aspects, occupying an intermediate position in terms of exertion.

What you cannot deduce from this is which substance is “best” for an individual or for trauma processing. Trauma, safety, and therapy are context-sensitive. Factors such as preparation, professional support, contraindications, aftercare, and personal stability are at least as decisive as the substance itself.

Additionally, combining substances, such as MDMA with psilocybin, is something that is discussed in some circles. In general, combining increases complexity and unpredictability, and can increase physical and mental strain. Without medical supervision and without a proper understanding of the risks, this is not something to be approached lightly.

Harm reduction: key practical considerations in outline

Apart from substance choice, these types of studies show why harm reduction is more than just “a dose.” Consider: clear intention, a safe setting, sober support, sufficient time for the entire duration of the effect, and realistic expectations. It is also wise to plan room for recovery and reintegration, precisely because the impact does not always cease when the acute effects subside.

Because there are significant individual differences, it is wise to critically evaluate sources of information and not use a single graph or personal story as a guideline. Research results are valuable, but they remain averages. Personal stories can resonate, but are by definition subjective.

Conclusion

In this double-blind comparison, clear differences emerged: psilocybin produced, on average, the strongest and longest-lasting effects, with the highest scores on perceptual and mystical dimensions, but also the most anxiety, nausea, and unpleasant effects. MDMA was, on average, slightly lower in overall intensity, remained relatively low on anxiety, and primarily showed social and opening effects. 2C-B 30 mg often occupied a middle position, exhibiting both psychedelic and entactogenic characteristics.

Those considering guided sessions would do well to view these differences as guidelines, not predictions. Currently, MDMA sessions can only be discussed within scientific research or in practice via harm reduction. If you would like to learn more about the possibilities and methods, you can register via https://mdmatherapie.nl/aanmelden-mdma-sessie/.